<DOC>
	<DOCNO>NCT00195702</DOCNO>
	<brief_summary>The purpose study assess safety , immunogenicity , clinical efficacy adalimumab compare placebo ( double-blind phase ) evaluate long-term safety maintenance efficacy follow repeat administration adalimumab ( open-label extension phase ) patient persistently active rheumatoid arthritis receive concurrent methotrexate therapy .</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate .</brief_title>
	<detailed_description>This 10-year study initial 52-week , double-blind , placebo-controlled phase follow open-label extension phase 9 year duration . Data analyze double-blind phase use patient randomize receive least one dose study drug Week 52 patient receive least one dose adalimumab 10-year study ( Intent-to-Treat [ ITT ] population ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Age 18 old good health ( Investigator discretion ) recent stable medical history Met American College Rheumatology ( ACR ) criteria diagnosis active rheumatoid arthritis ( RA ) screen baseline visit &gt; =6 swollen joint &gt; =9 tender joint , despite minimum 3months treatment methotrexate ( MTX ) . ( Distal interphalangeal joint [ DIPs ] include joint count inclusion . The screen baseline visit could 3 28 day apart patient previously receive diseasemodifying antirheumatic drug [ DMARDs ] MTX 4 6 week patient require DMARD washout period . ) Insufficient efficacy MTX 12.5 25 mg per week ( 10 mg per week MTX intolerant ) . If patient secondline treatment ( DMARD ) MTX , he/she discontinue least 28 day baseline visit ( washout period ) . Treatment oral folic acid 13 mg/day , appropriate , 10 mg leucovorin per week . Both rheumatoid factor positivity Creactive protein value &gt; =1 mg/dL , least one joint erosion Xray . Subject consider investigator , reason , unsuitable candidate study . Female subject pregnant breastfeeding consider become pregnant . Preceding treatment tumor necrosis factor ( TNF ) antagonist , include adalimumab . Prior exposure alkylating agent , chlorambucil cyclophosphamide . Intraarticular , intramuscular , intravenous administration corticosteroid within 4 week prior screen visit . Subject wheelchair bound bedridden .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>